Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia
Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia
PI3K is critical for the normal function of the immune system, however dysregulated PI3K mediated signaling has been linked to the development of many immune mediated pathologies. This review describes current progress in the development of isoform-specific PI3K inhibitors that hold promise for the treatment of hematopoietic malignancies as well as for inflammatory and autoimmune diseases. A SH2-domain containing inositol-5-phosphatase (SHIP) is a regulator of PI3K signaling, and is also discussed as a potential drug target for immunomodulation and the treatment of leukemia. Recent progress has been made in the development of small molecule compounds that potently and selectively modulate SHIP activity and hence provide a novel mechanism to alter PI3K mediated signaling.
444-451
Blunt, Matthew D.
b1109de3-6045-4bc3-bd77-6cf26504697d
Ward, Stephen G.
055fb146-f745-4b52-abf5-10d9de7e1673
August 2012
Blunt, Matthew D.
b1109de3-6045-4bc3-bd77-6cf26504697d
Ward, Stephen G.
055fb146-f745-4b52-abf5-10d9de7e1673
Blunt, Matthew D. and Ward, Stephen G.
(2012)
Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia.
Current Opinion in Pharmacology, 12 (4), .
(doi:10.1016/j.coph.2012.02.015).
(PMID:22483603)
Abstract
PI3K is critical for the normal function of the immune system, however dysregulated PI3K mediated signaling has been linked to the development of many immune mediated pathologies. This review describes current progress in the development of isoform-specific PI3K inhibitors that hold promise for the treatment of hematopoietic malignancies as well as for inflammatory and autoimmune diseases. A SH2-domain containing inositol-5-phosphatase (SHIP) is a regulator of PI3K signaling, and is also discussed as a potential drug target for immunomodulation and the treatment of leukemia. Recent progress has been made in the development of small molecule compounds that potently and selectively modulate SHIP activity and hence provide a novel mechanism to alter PI3K mediated signaling.
This record has no associated files available for download.
More information
e-pub ahead of print date: 4 April 2012
Published date: August 2012
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 392721
URI: http://eprints.soton.ac.uk/id/eprint/392721
ISSN: 1471-4892
PURE UUID: 6aa7416f-9add-45c5-bc8b-256427511f55
Catalogue record
Date deposited: 14 Apr 2016 14:35
Last modified: 15 Mar 2024 03:46
Export record
Altmetrics
Contributors
Author:
Stephen G. Ward
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
